|
|||||
|
|
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy |
|
| Authors: | G.G. Hanna L. Murray R. Patel S. Jain K.L. Aitken K.N. Franks N. van As A. Tree P. Hatfield S. Harrow F. McDonald M. Ahmed F.H. Saran G.J. Webster V. Khoo D. Landau D.J. Eaton M.A. Hawkins |
| Affiliation: | 1. Centre for Cancer Research and Cell Biology, Queen’s University of Belfast, Belfast, UK;4. Department of Clinical Oncology, St James’s Institute of Oncology, Leeds Cancer Centre, Leeds, UK;2. National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, UK;3. Department of Radiotherapy, Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, UK;5. Department of Radiotherapy, Beatson West of Scotland Cancer Centre, Glasgow, UK;1. Department of Radiotherapy, Worcester Oncology Centre, Worcester, UK;2. Department of Oncology, Guy’s and St Thomas’ Hospital, London, UK;3. CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK |
| Abstract: | Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between SABR studies and internationally. |
| Keywords: | Constraints normal tissue OAR SABR SBRT stereotactic radiotherapy |
| 本文献已被 ScienceDirect 等数据库收录！ | |